Decision-Making Patterns for Clinically Node-Positive, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: Insights From a Survey of Breast Cancer Experts.

ABSTRACT:

Purpose

In hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the omission of chemotherapy has become a viable option for select patients. However, when lymph node (LN) metastasis is suspected at diagnosis, the optimal initial treatment strategy (upfront surgery, neoadjuvant chemotherapy, or genomic testing) remains controversial. This study aimed to assess the preferences of multinational breast cancer specialists and to identify the factors influencing clinical decisions in this setting.

Methods

A cross-sectional survey was conducted among breast cancer specialists at two time points: November 2023 (via the Korean Breast Cancer Society) and April 2024 (following the Asian Breast Cancer Network meeting at Global Breast C

SUBMITTER: Kook Y 

PROVIDER: S-EPMC12599463 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature